A groundbreaking study published in the March 2026 issue of the Journal of the National Comprehensive Cancer Network (JNCCN) reveals that a tailored exercise regimen can significantly mitigate cognitive decline in cancer patients undergoing chemotherapy administered on a biweekly schedule. This landmark phase III randomized controlled trial, conducted across multiple centers nationwide, demonstrates that integrative physical activity could serve as a powerful adjunctive intervention to preserve mental acuity during the rigors of chemotherapy.
Chemotherapy-induced cognitive impairment, colloquially termed “chemo brain,” affects a substantial proportion of cancer patients, manifesting as difficulties with memory, attention, and executive function. It is well-known that chemotherapy agents, while targeting malignant cells, also can induce neurotoxic effects that impinge on neural networks responsible for cognitive processes. Yet, effective, accessible strategies to alleviate these symptoms have remained elusive.
This innovative trial investigated the impact of Exercise for Cancer Patients (EXCAP©®), an individualized program combining walking and resistance band exercises, designed to be safely performed at home. The study’s 687 participants were drawn from 20 community oncology practices affiliated with the University of Rochester’s NCI Community Oncology Research Program (NCORP) Research Base. Importantly, enrolled patients were chemotherapy-naïve and lacked distant metastases, with the cohort predominantly consisting of women with breast cancer who had undergone surgical intervention.
The EXCAP intervention was delivered using a “teach-back” educational approach to ensure that patients mastered proper exercise techniques. Participants logged daily step counts with pedometers and recorded time spent performing resistance exercises, enabling precise adherence monitoring. The critical finding was that patients receiving chemotherapy every two weeks who followed the EXCAP protocol displayed significantly less cognitive decline and reported reduced mental fatigue compared to counterparts who received standard care without structured exercise.
Strikingly, these cerebral benefits were not mirrored in patients undergoing chemotherapy cycles of three to four weeks. Researchers hypothesize that the biweekly chemotherapy schedule may provide an optimal window for physiological recovery, thereby facilitating greater engagement in physical activity and its neuroprotective effects. This finding suggests a nuanced interaction between chemotherapy timing and adjunctive interventions that warrants deeper investigation.
Lead author Dr. Karen M. Mustian, PhD, MPH of the Wilmot Cancer Institute emphasized the clinical significance of these findings, stating that incorporating exercise prescriptions into routine chemotherapy care could profoundly enhance supportive oncology care paradigms. By advocating for structured, home-based physical activity, care providers can empower patients to maintain cognitive function and quality of life during arduous treatment courses.
Complementing this perspective, co-lead investigator Dr. Po-Ju Lin, PhD, MPH, RD, highlighted the accessibility and safety profile of non-pharmacologic interventions like exercise, cognitive training, and mindfulness techniques. These strategies circumvent the barriers posed by costly or clinic-bound therapies and align with patient-centered models of care that prioritize feasibility and self-management.
Beyond cognitive outcomes, EXCAP participants maintained consistent ambulatory activity during chemotherapy, whereas those not enrolled reduced their walking by over 50%. This preservation of physical mobility may independently contribute to improved neurocognitive resilience, underscoring the interplay between physical and cerebral health in oncology populations.
The trial’s robust multicenter design and sizable cohort lend substantial weight to the validity of the results, though the authors acknowledge potential limitations. The specific chemotherapy regimens and individual patient variables that might modulate exercise benefits require further elucidation. Moreover, expanding studies to more diverse populations will be essential to generalize these findings across different cancer subtypes and treatment protocols.
Medical oncologist Dr. Lindsay L. Peterson, MD, MSCR, who was not involved in the research, affirmed the broader clinical implications. She noted that fostering cognitive clarity during cancer treatment is pivotal not only for maintaining patient independence but also for enabling continued occupational and familial engagement. This study thus informs survivorship care guidelines and highlights exercise as a tangible intervention to combat chemotherapy-related neurotoxicity.
The study reinforces current recommendations articulated in the NCCN Clinical Practice Guidelines for Survivorship, which endorse routine physical activity for cancer survivors experiencing cognitive dysfunction. Importantly, the guidelines offer comprehensive safety parameters to tailor exercise programs to individual patient capacity, ensuring interventions are both effective and safe.
For patients and caregivers eager to translate these findings into practice, the NCCN Guidelines for Patients provide accessible instructions on safe exercise habits during and following cancer treatment. This resource empowers individuals with evidence-based strategies to actively participate in their cognitive and physical health maintenance during challenging treatment phases.
In summary, this pioneering clinical trial introduces compelling evidence that structured, individualized exercise regimens can attenuate cognitive decline associated with biweekly chemotherapy, offering a non-pharmacologic, low-cost approach to enhancing the neurocognitive wellbeing of patients. As the oncology community strives to optimize supportive care, integrating exercise into chemotherapy protocols may emerge as a transformative standard of care, improving patient outcomes and quality of life.
Subject of Research: People
Article Title: Effects of Exercise on Cognitive Impairment in Patients Receiving Chemotherapy: A Multicenter Phase III Randomized Controlled Trial
News Publication Date: 12-Mar-2026
Web References:
JNCCN: https://www.jnccn.org/
Full study: https://jnccn.org/view/journals/jnccn/24/3/article-p91.xml
NCCN Guidelines for Patients—Survivorship Care for Healthy Living: https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients/guidelines-for-patients-details?patientGuidelineId=52
References:
Mustian KM, Lin PJ, et al. Effects of Exercise on Cognitive Impairment in Patients Receiving Chemotherapy: A Multicenter Phase III Randomized Controlled Trial. JNCCN. 2026;24(3):91–104. DOI: 10.6004/jnccn.2025.7118
Image Credits: NCCN
Keywords: Cancer, Oncology, Physical exercise, Health care delivery, Patient monitoring, Cancer patients, Chemotherapy, Mental fatigue
Tags: biweekly chemotherapy cognitive effectscancer patient cognitive healthchemo brain in cancer patientschemotherapy-induced cognitive impairmentcognitive decline mitigation chemotherapyEXCAP exercise program for cancerintegrative physical activity cancer therapyphase III randomized controlled trial exercisestructured exercise programs for chemo braintailored exercise regimen cancer patientsUniversity of Rochester NCORP studywalking and resistance band exercises cancer
